Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Night vision test may spot early eye disease

NCT ID NCT04112667

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 556 people to understand how night vision problems are connected to early age-related macular degeneration (AMD). Participants took vision tests and had detailed eye imaging. The goal was to find reliable markers that could help design future treatments for AMD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify reliable markers for early AMD, paving the way for future treatments.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

556 people

The number who actually took part.

Started

Oct 2019

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

group 1 is \>=60 years old with normal macular health group 2 is \>=60 years old with early AMD group 3 is 20-30 years old are Young Normals

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For those in Normal Macular Health or Early AMD: aged ≥ 60 years; either have normal macular health in both eyes at baseline or have early AMD in one eye For Young Normals: aged 20-30 years old; normal macular health in both eyes. Exclusion Criteria: Exclusion for those in normal macular health are: * ANY EYE CONDITION OR DISEASE IN EITHER EITHER (OTHER THAN EARLY CATARACT) THAT CAN IMPAIR VISION INCLUDING: * diabetic retinopathy * glaucoma * ocular hypertension * history of retinal diseases (e.g., retinal vein occlusion, retinal degenerations) * optic neuritis * corneal disease * previous ocular trauma or surgery * REFRACTIVE ERROR \>- 6 DIOPTERS * NEUROLOGICAL CONDITIONS THAT CAN IMPAIR VISION OR JUDGEMENT INCLUDING: * multiple sclerosis * Parkinson disease * stroke * Alzheimer disease * seizure disorders * brain tumor * traumatic brain injury * PSYCHIATRIC DISORDERS THAT COULD IMPAIR THE ABILITY: * to follow simple directions * answer questions about health and functioning * or to provide informed consent * DIABETES * ANY MEDICAL CONDITION THAT CAUSES SIGNIFICANT FRALITY OR IS BELIEVED TO BE TERMINAL. Exclusion criteria for the early AMD group: These are identical to those described above, except that it is acceptable for participants to have early AMD (AREDS 2-4) in one eye and be AREDS grade 1 or any stage of AMD in the fellow eye. Exclusion for Young Normals: * ANY EYE CONDITION OR DISEASE IN EITHER EYE (OTHER THAN EARLY CATARACT) THAT CAN IMPAIR VISION INCLUDING: * diabetic retinopathy * glaucoma * ocular hypertension * history of retinal diseases (e.g., retinal vein occlusion, retinal degenerations) * optic neuritis, corneal disease * previous ocular trauma or surgery * RERACTIVE ERROR \>=6 DIOPTORS * NEUROLOGICAL CONDITIONS THAT CAN IMPAIR VISION OR JUDGEMENT INCLUDING: * multiple sclerosis * Parkinson disease * stroke * Alzheimer disease * seizure disorders * brain tumor * traumatic brain injury * PSYCHIATRIC DISORDERS THAT COULD IMPAIR THE ABILITY TO: * follow simple directions * answer questions about health and functioning * or to provide informed consent * DIABETES * ANY MEDICAL CONDITION THAT CAUSES SIGNIFICANT FRAILTY OR IS BELIEVED TO BE TERMINAL.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.